NCT05985707View on ClinicalTrials.gov

KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 15, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
HER2-positive Colorectal CancerHER2-positive Biliary Tract Cancer
Interventions
DRUG

KN026

KN026 is a novel bispecific antibody that simultaneously binds to two distinct HER2 epitopes.

DRUG

KN046

KN046 is a novel bispecific antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.

DRUG

XELOX

XELOX is the standard first-line chemotherapy in metastatic colorectal cancer and biliary duct cancer.

Trial Locations (1)

100142

Peking University cancer hospital & institution, Beijing

All Listed Sponsors
lead

Peking University Cancer Hospital & Institute

OTHER

NCT05985707 - KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma | Biotech Hunter | Biotech Hunter